When analysing the patients with information available on the extracellular mucin status, both AC (n = 1397) and MAC (n = 215) had better 5-year OS rates at 70% (95% CI 68–73) and 62% (95% CI 58–73), respectively, compared to the SRC tumour patients (p < 0.001, Figure 4b). This evidence concerns the gene MUC5AC and neoplasm.